Our Story
Our Brands
Newsroom
Investors
Contact
The House Judiciary Committee in the U.S. passed the Marijuana Opportunity, Reinvestment and Expungement ("MORE") Act in a 24-10 vote on Wednesday. If passed, the MORE Act would decriminalize cannabis at the federal level.
Mildly positive.
The MORE Act was approved by the House Judiciary Committee, the congressional subcommittee that oversees the administration of justice in the U.S. While this indicates positive momentum for the decriminalization of cannabis on a federal level, and is a historic event in and of itself, this approval was largely ceremonial as the MORE Act faces a long road to potential passage.
The MORE Act's passage represents the first time a congressional committee has ever debated and voted on the specific mechanics of how cannabis could be legalized on the federal level. However, the ultimate passage of the Act still faces significant headwinds, especially in the Senate, owing to political realities in the U.S. The House vote was mostly along party lines, and the little bipartisan support offered by Republicans on the House Judiciary Committee suggests that further compromises may be required ahead of the MORE Act's potential reading on the floor of the House.
Momentum appears to be building for an overhaul of cannabis enforcement from the justice department. This, in conjunction with the USDA's draft Hemp Regulations clarifying the rules on interstate transfer of CBD isolate derived from hemp, suggest that U.S. lawmakers are paying attention to mounting public support for modernizing cannabis laws. In that regard, yesterday’s vote is a good news story.
This is not an offer to sell or a recommendation to trade in any securities. This information is provided as of the date hereof. This document contains data obtained from third parties that Canopy Rivers has not independently verified. This document also contains forward-looking information within the meaning of Canadian securities law, which is based on certain assumptions. While management believes these assumptions are reasonable based on information available as of the current date, they may prove to be incorrect. Many assumptions are based on factors outside of Canopy Rivers’ control and actual results may differ materially from current expectations. Forward-looking information involves risks, including, but not limited to, the risk factors set out in Canopy Rivers’ most recent Management’s Discussion and Analysis and Annual Information Form. You should not place undue reliance on forward-looking information. Except as required by applicable law, Canopy Rivers assumes no obligation to update or revise any forward-looking information to reflect new events or circumstances.
You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of our emails. By entering your email, you are indicating your acceptance of our privacy policy and terms of use.
Please select how you would like to hear from RIV Capital:
By providing your personal information to us, you consent to our disclosure of this information to our service providers (and other third parties) as described in our privacy policy, including those that may be located outside of your jurisdiction of residence, for the purposes of processing your personal information on our behalf, providing services to us or to you, operating and hosting our website and business and for the other purposes described in our privacy policy.
We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.
Yes, I’m definitely at least twenty-one (21) years of age or am otherwise a qualified patient.